skip to Main Content

LED Medical Diagnostics Selected for “Top 50 Technology Products” Award for the VELscope Vx

  • January 15, 2014
  • News Releases

BURNABY, British Columbia – November 20, 2012 –LED Medical Diagnostics Inc. (“LED Medical” or “the company”), is proud to announce that the VELscope Vx Enhanced Oral Assessment System, the market-leading early-stage oral cancer detection device approved by the FDA, Health Canada, and European regulators, has been chosen by Dentistry Today magazine for one of its annual “Top 50 Technology Products” awards. Dentistry Today’s “Top 50 Technology Products” represent the best and brightest technologies available to dental professionals each year. The recipients are determined based on input from readers of Dentistry Today.

“We are honoured and pleased to receive this Readers’ Choice award from Dentistry Today magazine,” said LED’s founder and CEO, Peter Whitehead. “Dental professionals around the world are realizing that they have a crucial role to play in the detection of oral cancer, and that the VELscope Vx is the best available tool for helping them find this devastating disease in its earliest stages. The fact that this award was based on the input of the magazine’s readership – dental professionals – is particularly gratifying.”

About LED Medical Diagnostics Inc.

LED Medical Diagnostics Inc. was founded in 2003 and is headquartered in Burnaby, British Columbia, Canada. Its wholly-owned subsidiary, LED Dental Inc., is the manufacturer of the Velscope Vx Enhanced Oral Assessment System. Velscope Vx devices, the first to apply tissue fluorescence visualization technology to the oral cavity, are used to conduct more screenings for oral cancer and other oral diseases than any other adjunctive device in the world. To date, the VELscope has sold over 12,000 units, and been used to perform an estimated 25-million exams. For more information, call +1 (604) 434-4614, or visit

About the VELscope Vx

The Velscope Vx is a powerful FDA-approved tool used to screen for oral cancer. It saves lives and decreases morbidity by helping clinicians detect early stage oral cancer, pre-cancer, and other abnormalities in the mouth such as viral, fungal and bacterial infections. For more information please call +1 (604) 434-4614, or visit

This press release contains statements which, to the extent that they are not recitations of historical fact, may constitute forward-looking information under applicable Canadian securities legislation that involve risks and uncertainties. Such forward-looking statements or information include statements regarding the Company’s future product sales. Persons reading this press release are cautioned that such statements or information are only predictions, and that the Corporation’s actual future results or performance may be materially different. Factors that could cause actual events or results to differ materially from those suggested by these forward-looking statements include, but are not limited to competition risks, distributor risks and other factors described in the Corporation’s reports filed on SEDAR including its Annual Information Form and financial report for the year ended December 31, 2011. This list is not exhaustive of the factors that may affect the Company’s forward-looking information. These and other factors should be considered carefully and readers should not place undue reliance on such forward-looking information. All forward-looking statements made in this press release are qualified by this cautionary statement and there can be no assurance that actual results or developments anticipated by the Company will be realized. The Company disclaims any intention or obligation to update or revise forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.

Back To Top